FocusSprint VR: 4-Week Supervised Immersive Attention Course for Pediatric ADHD

Concept

FocusSprint VR is a clinic-delivered immersive virtual-reality attention course for children with ADHD: eight supervised head-mounted-display sessions over four weeks (~30 minutes each) of attention-demanding immersive tasks — the class of intervention tested across the seven randomized trials in the new meta-analysis — bookended by a short attention and memory check at intake and course completion.

The commercial wedge is one short, standardized protocol rather than a personalized or long program:

• Short course. The meta-regression found intervention length did not moderate the effect on global cognitive functioning (p = 0.59), so the product ships as a 4-week course instead of the 10–12-week programs typical of cognitive training — cutting clinic time and cost per child.
• One protocol for the whole pediatric range. Participant age did not moderate effects (p = 0.70), so a single course serves the full child/adolescent caseload without age-tiered content.
• Add-on, not replacement. Control-group type (active vs passive) did not moderate effects, so the course is positioned alongside existing care (medication, psychotherapy) rather than instead of it.
• Supervised clinic delivery matches the demonstrated setup of the trials; unsupervised home use is not claimed.
• Honest evidence sizing. Marketing leads with the best-supported outcome — attention (g = 0.94, pooled across all 7 RCTs) — while the large memory estimate (g = 1.81, from a single trial) is presented as promising; the built-in pre/post checks generate the real-world outcome data the field lacks, since the review itself flags poor study quality and small samples.

Why now

• The first meta-analysis of immersive VR for pediatric ADHD cognition pools 7 RCTs and finds large effects on attention (g = 0.94) and global cognitive functioning (g > 0.80), with a large memory effect (g = 1.81) from one trial.
• Safety and adherence are cleared for supervised rollout: no adverse effects, and drop-out risk comparable to controls (RR = 1.45, p = 0.53).
• Dosing is simplified by the meta-regression: length (p = 0.59), age (p = 0.70), control type, and even head-mounted-display novelty all failed to moderate effects — the specific findings that justify a single short standardized course and support that gains are not just excitement about new headsets.
• Digital therapeutics already show pooled efficacy in children and adolescents with ADHD [1], and guideline groups are explicitly calling for evidence to be brought into the clinic [5] — but with the evidence base acknowledged as low quality, a supervised, measurement-bearing, modestly-claimed course is the correctly sized first product.